Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort study in Shanghai

Bo Zheng, Bronner Gonçalves, Pengfei Deng, View ORCID ProfileWeibing Wang, Jie Tian, Xueyao Liang, View ORCID ProfileYe Yao, Caoyi Xue
doi: https://doi.org/10.1101/2024.01.09.24301069
Bo Zheng
1Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bronner Gonçalves
2Department of Comparative Biomedical Sciences, School of Veterinary Medicine, University of Surrey, Guildford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pengfei Deng
3Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, 200120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Weibing Wang
1Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
4Key Laboratory of Public Health Safety of Ministry of Education, Fudan University, Shanghai 200032, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Weibing Wang
Jie Tian
1Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xueyao Liang
1Department of Epidemiology, School of Public Health, Fudan University, Shanghai 200032, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ye Yao
5School of Public Health, Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai 200032, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ye Yao
  • For correspondence: yyao{at}fudan.edu.cn xuecaoyi83{at}163.com
Caoyi Xue
3Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai, 200120, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yyao{at}fudan.edu.cn xuecaoyi83{at}163.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

ABSTRACT

Background In many settings, a large fraction of the population has both been vaccinated against and infected by SARS-CoV-2. Hence, quantifying the protection provided by post-infection vaccination has become critical for policy. We aimed to estimate the protective effect against SARS-CoV-2 reinfection of an additional vaccine dose after an initial Omicron variant infection.

Methods We report a retrospective, population-based cohort study performed in Shanghai, China, using electronic databases with information on SARS-CoV-2 infections and vaccination history. We compared reinfection incidence by post-infection vaccination status in individuals initially infected during the April-May 2022 Omicron variant surge in Shanghai and who had been vaccinated before that period. Cox models were fit to estimate adjusted hazard ratios (aHR).

Results 275,896 individuals were diagnosed with RT-PCR-confirmed SARS-CoV-2 infection in April-May 2022; 199,312/275,896 were included in analyses on the effect of a post-infection vaccine dose. Post-infection vaccination provided protection against reinfection (aHR 0.82; 95% CI 0.79-0.85). For patients who had received one, two or three vaccine doses before their first infection, hazard ratios for the post-infection vaccination effect were 0.84 (0.76-0.93), 0.87 (0.83-0.90) and 0.96 (0.74-1.23), respectively. Vaccination within 30 and 90 days before the second Omicron wave provided different degrees of protection (in aHR): 0.51 (0.44-0.58), and 0.67 (0.61-0.74), respectively. Moreover, for all vaccine types, but to different extents, a post-infection dose given to individuals who were fully vaccinated before first infection was protective.

Conclusions In previously vaccinated and infected individuals, an additional vaccine dose provided protection against Omicron variant reinfection. These observations will inform future policy decisions on COVID-19 vaccination in China and other countries.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was granted by the Key Discipline Program of Pudong New Area Health System [Grant No. PWZxk2022-25]; the Development and Application of Intelligent Epidemic Surveillance and Artificial Intelligence Analysis System [Grant No. 21002411400]; the Shanghai Three-year Action Plan to Strengthen the Construction of Public Health System [Grant No. GWVI-11.2-XD08]. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Ethical Review Committee in the Shanghai Pudong New Area Center for Disease Control and Prevention (approval number: PDCDCLL-20220801-001).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 10, 2024.
Download PDF
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort study in Shanghai
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort study in Shanghai
Bo Zheng, Bronner Gonçalves, Pengfei Deng, Weibing Wang, Jie Tian, Xueyao Liang, Ye Yao, Caoyi Xue
medRxiv 2024.01.09.24301069; doi: https://doi.org/10.1101/2024.01.09.24301069
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Protection afforded by post-infection SARS-CoV-2 vaccine doses: a cohort study in Shanghai
Bo Zheng, Bronner Gonçalves, Pengfei Deng, Weibing Wang, Jie Tian, Xueyao Liang, Ye Yao, Caoyi Xue
medRxiv 2024.01.09.24301069; doi: https://doi.org/10.1101/2024.01.09.24301069

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13375)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14627)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1705)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)